Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography

Table 2 Studies reporting treatment outcomes for ONB

Author	Year	Period	Patients (n)	Treatment	Follow up (mo)	5-year OS	Other Survival (yr)
Gruber [14]	2002	1980-2001	28	Surgery + Pre-/PostopRT or RT +/− CTX	68	77%	DFS 70% (5 yr)
Eich [5]	2003	1979-2001	47	Surgery only, Surgery + PostopRT, RT +/− CTX or multimodality therapy	65	64%	EFS 50% (5 yr)
Diaz [7]	2005	1979-2002	30	Surgery only, Surgery + Pre-/PostopRT or RT +/− CTX	87	89%	RFS 69% (5 yr)
Ozsahin [6]	2010	1971-2004	77	Surgery only, Surgery + RT, RT +/− CTX or multimodality therapy	72	64%	DFS 57% (5 yr)
Platek [2]	2011	1973-2006	511	Surgery only, Surgery + RT, RT only or neither surgery nor RT	–	73% Surgery + RT,	–
						68% Surgery only,
						35% RT only,
						26% neither surgery nor RT
Modesto [9]	2013	1998-2010	43	multimodality therapy	77	65%	PFS 57% (5 yr)
Present study	–	1992-2013	17	Surgery + PostopRT, PreopRT + Surgery or multimodality therapy	95	88%	RFS 74% (5 yr)

Abbreviations: RT (radiotherapy), PostopRT (postoperative radiotherapy), CTX (chemotherapy), DFS (disease-free survival), EFS (event-free survival), RFS (relapse-free survival), PFS (progression-free survival).

ISSN: 1748-717X